)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Belite Bio (BLTE) investor relations material
Belite Bio Study Result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Result summary1 Dec, 2025
Study background and design
The DRAGON Phase 3 trial was a 24-month, multicenter, randomized, double-masked, placebo-controlled study in adolescents aged 12–20 years with Stargardt disease and at least one ABCA4 mutation, enrolling 104 patients globally.
Participants were randomized 2:1 to receive 5 mg/day oral Tinlarebant or placebo, with balanced baseline characteristics between groups.
The primary endpoint was the annualized rate of lesion growth in definitely decreased autofluorescence (DDAF) at 25 months, with key secondary endpoints including total decreased autofluorescence (DAF), best-corrected visual acuity (BCVA), and safety.
Tinlarebant is an oral, once-daily small molecule targeting RBP4 to reduce vitamin A delivery to the eye, aiming to slow retinal degeneration.
Efficacy results
Tinlarebant achieved a statistically significant 36% reduction in DDAF lesion growth rate versus placebo (p=0.0033), with consistent results in sensitivity analyses.
The treatment effect was confirmed in the fellow eye, showing a 33.6% reduction in lesion growth (p=0.041).
DAF lesion growth, a key secondary endpoint, was slowed by 33.7% in the study eye (p=0.027) and 32.7% in the fellow eye (p=0.017), both statistically significant.
Visual acuity (BCVA) remained stable in both groups over two years, consistent with disease natural history.
Tinlarebant reduced RBP4 levels by about 80% from baseline, exceeding the 70% target associated with clinical benefit.
Safety and tolerability
Tinlarebant demonstrated an excellent safety profile, with no serious treatment-related adverse events or deaths over two years.
Most adverse events were mild and included nasopharyngitis, headache, acne, xanthopsia, and delayed dark adaptation; most resolved during treatment.
Four treatment-emergent adverse events led to drug discontinuation, with about half likely related to ocular events.
No discontinuations were due to non-ocular adverse events; six serious non-ocular AEs occurred, none related to the drug.
The safety profile supports long-term compliance and chronic use in adolescents.
How will regulators view broad label for Tinlarebant?
Address payer concerns on stable BCVA data
Sustaining adherence for chronic Tinlarebant?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Belite Bio earnings date
Q4 202513 Mar, 2026
Next Belite Bio earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Belite Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing novel therapeutics targeting retinal degenerative eye diseases and certain metabolic diseases. The company's primary focus includes conditions such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease type 1 (STGD1), which can lead to permanent blindness. Additionally, Belite Bio is exploring treatments for metabolic disorders like non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Belite Bio, Inc. was founded in 2016 and is headquartered in San Diego, California. The company's shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage